Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2026
Filing Date: May 6, 2026
Principal Executive Office: Jena, Germany
This filing incorporates by reference the Unaudited Condensed Consolidated Financial Statements (Exhibit 99.1) and Management's Discussion and Analysis (Exhibit 99.2) for the quarter ended March 31, 2026.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial statements or MD&A text. Consequently, the filing text does not provide a clear value for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Operating Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. Specific operational or financial variances are detailed in the incorporated exhibits (99.1 and 99.2), which are not included in the input content.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risk factors, contingencies, or unusual items. These disclosures are contained within the incorporated Management's Discussion and Analysis (Exhibit 99.2).
Investor Verification Checklist
- Review Exhibit 99.1 for the full Unaudited Condensed Consolidated Financial Statements to verify cash burn rate and liquidity.
- Review Exhibit 99.2 for Management's Discussion and Analysis to understand clinical trial progress and operational milestones.
- Confirm the status of registration statements on Form S-8 (File Nos. 333-221656 and 333-240185) and Form F-3 (File No. 333-273058) as referenced in the Explanatory Note.
- Verify the specific date of the financial statements against the filing date to ensure no subsequent material events have occurred.